Next 10 |
home / stock / vbizf / vbizf news
2023-07-23 05:45:00 ET Summary Novartis has signed a $1 billion deal to acquire DTx Pharma - DTx Pharma shareholders will receive $500 million upfront and up to $500 million in milestones. Sichuan Kelun-Biotech completed a $174 million IPO on the Hong Kong Exchange, valuing the co...
2023-06-21 06:40:00 ET Summary As well as tapping strategic investors, Viva Biotech is planning to list its drug research subsidiary on a Chinese exchange by the end of 2026. A sinking share price has piled pressure on the company to buy back its convertible bonds, hence the need ...
Viva Biotech’s eked out a scant 5% revenue growth in the first half of the year and fell into the red, even as other peers in China’s CXO sector performed much better. Changing values of the company’s investments are largely behind big fluctuations in its performa...
Viva Biotech’s fivefold jump in first-half revenues and move back to profitability come on the back of its acquisition last year of two contract drug makers. Company’s shift to contract drug making comes as global pharma firms shift focus to drug development. Founded...
Viva Biotech Holdings (VBIZF): FY Non-GAAP EPS of RMB0.18.Revenue of RMB697M (+115.7% Y/Y)Press Release For further details see: Viva Biotech Holdings reports FY 2020 results
Illumina will acquire Grail, an Illumina spin-out that is developing an early screening test for multiple forms of cancer, for $8 billion in cash and stock. Sequoia Capital China is raising $2.2 billion for a new yuan-denominated fund, the company's sixth fund. Sinovac Biotech ann...
Viva Biotech Holdings ( OTCPK:VBIZF ) : 1H Non-GAAP EPS of RMB0.09. Revenue of RMB197.6M (+38.9% Y/Y) Press Release More news on: Viva Biotech Holdings, Earnings news and commentary,
LianBio Launches to Bring US Assets to China; Announces $719 Million of In-Licensings Perceptive Advisors is launching LianBio to bring US biopharma assets to China. A successful fund operator, Perceptive has made investments in 150 public and 80 private biopharmas and has strong connectio...
Deals and Financings Shanghai Hansoh Pharma (HK: 3692) obtained Greater China rights to a BCR-ABL inhibitor discovered by Terns Pharma of California. Hansoh will make an upfront payment plus milestones of up to $68 million. It will also pay royalties on sales. TRN-000632 is an investigatio...
Schrödinger (NASDAQ: SDGR ) will collaborate with Viva Biotech Holdings ( OTCPK:VBIZF ) to expand the reach of structure-based drug discovery via generating de novo crystal structures of high-value targets. More news on: Schrödinger, Inc., Viva Biotech Holdings, Health...